Kraus, F.; El Hajj, H.; Le Deley, M.-C.; Aissaoui, O.; Gachon, B.; Chevalier, A.; Abdeddaim, C.; Lemaire, A.-S.; Ben Haj Amor, M.; Sylla, D.;
et al. A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. Cancers 2021, 13, 4925.
https://doi.org/10.3390/cancers13194925
AMA Style
Kraus F, El Hajj H, Le Deley M-C, Aissaoui O, Gachon B, Chevalier A, Abdeddaim C, Lemaire A-S, Ben Haj Amor M, Sylla D,
et al. A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. Cancers. 2021; 13(19):4925.
https://doi.org/10.3390/cancers13194925
Chicago/Turabian Style
Kraus, Francois, Houssein El Hajj, Marie-Cécile Le Deley, Othman Aissaoui, Bertrand Gachon, Annick Chevalier, Cyril Abdeddaim, Anne-Sophie Lemaire, Mariem Ben Haj Amor, Dienabou Sylla,
and et al. 2021. "A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction" Cancers 13, no. 19: 4925.
https://doi.org/10.3390/cancers13194925
APA Style
Kraus, F., El Hajj, H., Le Deley, M.-C., Aissaoui, O., Gachon, B., Chevalier, A., Abdeddaim, C., Lemaire, A.-S., Ben Haj Amor, M., Sylla, D., Leblanc, E., Narducci, F., & Hudry, D.
(2021). A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. Cancers, 13(19), 4925.
https://doi.org/10.3390/cancers13194925
